The RheumNow Week in Review - 19 January 2018 Save
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the rising cost of adalimumab, infections in myositis, phyisician burnout, biologics in Still's disease and weight loss benefits in RA.
- Checkpoint inhibitor use in autoimmune and inflammatory disease (AID) pts is associated with higher rates of immune-related AE 44.4%) with half these being a flare of underlying AID. https://t.co/aNHIE86B8r
- NY Times article reports 2015 price of 2 syringes of Humira is $2669 in USA; $1362 in UK; $1253 in Spain; $822 in Switzerland and $552 in South Africa. https://t.co/ulZFTxsRBU
- RT @kdao2011 Let your patients know the benefits of the occasional swear word: Cursing can help us withstand pain and more. https://t.co/x3NVNiT5Ir … via @WSJ !#*/@!^$!
- Cohort study of 204 myositis pts shows 6.4% develop opportunistic infx (OI) - 55% occuring in 1st yr, strongly assoc w/ high dose Steroids, biologics use, fever @onset, 4+ immunosuppressive use https://t.co/jeE2si2av6
- Taiwan claims study of 18267 RA patients (vs 73k non-RA) - RA pts have 2 fold increase in Hearing loss; moreso in men, elderly; worse w/ HTN and CV comrobidities. Lower rates seen w/ all RA therapy, NSAIDs, Pred, DMARDs, TNFi https://t.co/TZSFKpXGmX
- Rheumatology Physician Burnout and Depression
- IL-1 and IL-6 Inhibition Preferred in Systemic JIA
- Weight Loss Linked to RA Improvement. https://t.co/1E3xSvFj35
- Laparoscopic Gastric Sleeve Compared to Bypass Bariatric Surgery